HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zed, P. J. Articles by Busser, J. R. Search for Related Content PubMed PubMed Citation Articles by Zed, P. J. Articles by Busser, J. R.

PETER J. ZED, B.SC., B.SC.(PHARM.), PHARM.D., is Pharmacotherapeutic Specialist—Emergency Medicine, CSU Pharmaceutical Sciences, Vancouver General Hospital (VGH), and Clinical Associate Professor, Faculty of Pharmaceutical Sciences, and Associate Member, Division of Emergency Medicine, Department of Surgery, University of British Columbia (UBC), Vancouver, Canada. LYNE FILIATRAULT, M.D.C.M., FRCPC, FACEP, is Attending Physician, Department of Emergency Medicine, VGH, and Clinical Assistant Professor, Division of Emergency Medicine, Department of Surgery, UBC. JAMES R. BUSSER, M.D., FRCPC, M.H.SC., is Attending Physician, Department of Medicine, VGH, and Clinical Assistant Professor, Division of General Internal Medicine, Department of Medicine, UBC.

Address correspondence to Dr. Zed at CSU Pharmaceutical Sciences, Vancouver General Hospital, 855 West 12th Avenue, Vancouver, British Columbia, Canada V5Z 1M9 (zed{at}interchange.ubc.ca).

Purpose. The efficacy, safety, and patient satisfaction of an emergency department (ED)-based outpatient program providing treatment for venous thromboembolic disease (VTD) were studied. Methods. A prospective cohort study of patients enrolled in a hospital outpatient VTD treatment program was conducted from June 1999 to September 2003. Endpoints included recurrent VTD at three and six months following discharge from the program, minor and major bleeding, and thrombocytopenia during the acute phase of therapy. Patient satisfaction was assessed with an 18-question survey that was mailed to all patients following discharge from the program. Results. A total of 162 patients were included. Of the 142 evaluable patients, no patient experienced recurrent VTD at three months, while at six months, 2 patients (1.4%; 95% confidence interval [CI], 0.2–5.0%) had recurrence. No patient experienced major bleeding or thrombocytopenia, while 4 (2.5%; 95% CI, 0.8–6.2%) had minor bleeding. Ninety-seven percent of the patients were comfortable having their condition treated on an outpatient basis, and 85.1% felt it was more convenient to return to the hospital daily for medications and assessment than to be admitted to the hospital. Overall, 97.7% of the respondents were satisfied or very satisfied with the treatment received in the outpatient program, and 94.0% said they would enroll again if future treatment was indicated. Conclusion. An ED-based outpatient VTD treatment program was safe and effective and appeared to achieve a high level of patient satisfaction. Index terms: Anticoagulants; Data collection; Hospitals; Patients; Thromboembolism; Toxicity